These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3753522)

  • 1. Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver.
    Birgersson C; Morgan ET; Jörnvall H; von Bahr C
    Biochem Pharmacol; 1986 Sep; 35(18):3165-6. PubMed ID: 3753522
    [No Abstract]   [Full Text] [Related]  

  • 2. Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.
    von Bahr C; Birgersson C; Morgan ET; Eriksson O; Göransson M; Spina E; Woodhouse K
    Xenobiotica; 1986 May; 16(5):391-400. PubMed ID: 3739365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
    Distlerath LM; Guengerich FP
    Proc Natl Acad Sci U S A; 1984 Dec; 81(23):7348-52. PubMed ID: 6594694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV; Brinn RU; Gram LF
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between nortriptyline and debrisoquine hydroxylation in the human liver.
    von Bahr C; Birgersson C; Blanck A; Göransson M; Mellström B; Nilsell K
    Life Sci; 1983 Aug; 33(7):631-6. PubMed ID: 6410141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic characterization of human liver microsomal cytochromes P-450 involved in the oxidation of debrisoquine, bufuralol and the carcinogen 2-acetylaminofluorene.
    McManus ME
    Pharmacol Ther; 1987; 33(1):47-53. PubMed ID: 2888142
    [No Abstract]   [Full Text] [Related]  

  • 8. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
    Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative metabolism of debrisoquine, 7-ethoxyresorufin and benzo(a)pyrene in liver microsomes from humans, and from rats treated with cytochrome P-450 inducers.
    Birgersson C; Blanck A; Woodhouse K; Mellström B; von Bahr C
    Acta Pharmacol Toxicol (Copenh); 1985 Aug; 57(2):117-20. PubMed ID: 4061088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
    Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
    FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
    Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
    Zanger UM; Vilbois F; Hardwick JP; Meyer UA
    Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants of human microsomal enzymes.
    Davies DS; Boobis AR
    Biochem Soc Trans; 1983 Aug; 11(4):459-60. PubMed ID: 6617977
    [No Abstract]   [Full Text] [Related]  

  • 14. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
    Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
    Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E; Steiner E; Ericsson O; Sjöqvist F
    Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
    Spina E; Steiner E; Dumont E; Dahlqvist R
    Psychopharmacol Ser; 1989; 7():201-5. PubMed ID: 2687858
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquine hydroxylation polymorphism and personality.
    Bertilsson L; Alm C; De Las Carreras C; Widen J; Edman G; Schalling D
    Lancet; 1989 Mar; 1(8637):555. PubMed ID: 2564084
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.
    Davies DS; Kahn GC; Murray S; Brodie MJ; Boobis AR
    Br J Clin Pharmacol; 1981 Jan; 11(1):89-91. PubMed ID: 7213514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.